clinical trial | Q30612 |
P3098 | ClinicalTrials.gov ID | NCT02446405 |
P6099 | clinical trial phase | phase III clinical trial | Q42824827 |
P767 | contributor to the creative work or subject | Cancer Trials Ireland | Q30268773 |
P17 | country | Canada | Q16 |
Ireland | Q27 | ||
United States of America | Q30 | ||
Australia | Q408 | ||
United Kingdom | Q145 | ||
New Zealand | Q664 | ||
P582 | end time | 2020-09-01 | |
P921 | main subject | metastatic prostate carcinoma | Q55779807 |
P2899 | minimum age | 18 | |
P1132 | number of participants | 1125 | |
P6153 | research site | University of Toronto | Q180865 |
Dana–Farber Cancer Institute | Q1159198 | ||
Griffith University | Q1202292 | ||
Christchurch Hospital | Q1278898 | ||
Royal Hobart Hospital | Q2171042 | ||
Auckland City Hospital | Q4819504 | ||
Cross Cancer Institute | Q5188247 | ||
Ottawa University | Q7109265 | ||
Royal Adelaide Hospital | Q7373582 | ||
Sir Charles Gairdner Hospital | Q7526207 | ||
Townsville Hospital | Q7830280 | ||
Waikato Hospital | Q7959998 | ||
Saint John Regional Hospital | Q14875635 | ||
CancerCare Manitoba | Q30282110 | ||
Chris O’Brien Lifehouse | Q30282252 | ||
Thunder Bay Regional Research Institute | Q30296451 | ||
Princess Alexandra Hospital | Q50573098 | ||
P1813 | short name | ENZAMET | |
P580 | start time | 2014-03-01 | |
P8363 | study type | interventional study | Q78089383 |
P1476 | title | Randomised Phase 3 Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: ENZAMET |
Search more.